Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

727 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T. Reinisch W, et al. Among authors: rutgeerts p. Gut. 2006 Aug;55(8):1138-44. doi: 10.1136/gut.2005.079434. Epub 2006 Feb 21. Gut. 2006. PMID: 16492717 Free PMC article. Clinical Trial.
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.
Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN, Hommes D, Rutgeerts P, Cortot A, Gaspari M, Cheng M, Pearce T, Sands BE. Reinisch W, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2010 Feb;16(2):233-42. doi: 10.1002/ibd.21038. Inflamm Bowel Dis. 2010. PMID: 19637334 Clinical Trial.
A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, Buchman AL, Bar-Meir S, Bokemeyer B, Goldin E, Maaser C, Mahadevan U, Seidler U, Hoffman JC, Homoky D, Plasse T, Powers B, Rutgeerts P, Hommes D; Semapimod-CD04/CD05 Investigators. Dotan I, et al. Among authors: rutgeerts p. Gut. 2010 Jun;59(6):760-6. doi: 10.1136/gut.2009.179994. Gut. 2010. PMID: 20551461 Clinical Trial.
Management of acute severe ulcerative colitis.
Van Assche G, Vermeire S, Rutgeerts P. Van Assche G, et al. Among authors: rutgeerts p. Gut. 2011 Jan;60(1):130-3. doi: 10.1136/gut.2009.192765. Epub 2010 Oct 28. Gut. 2011. PMID: 21030524 Review.
Anti-TNF agents in Crohn's disease.
Van Assche G, Rutgeerts P. Van Assche G, et al. Among authors: rutgeerts p. Expert Opin Investig Drugs. 2000 Jan;9(1):103-11. doi: 10.1517/13543784.9.1.103. Expert Opin Investig Drugs. 2000. PMID: 11060664 Review.
727 results